News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Following Success of Pilot, Cenix BioScience GmbH Takes on Second RNAi-Based Target Validation Project for CellCentric Ltd.



7/1/2008 10:08:06 AM

DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has initiated a second target validation project under the framework research agreement signed previously with UK-based CellCentric Ltd, a biotechnology company developing therapeutics against a series of novel epigenetic targets.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES